In spite of irs growing importance in tbe modern dissolution InboraUJry, 
Introduction
USP Apparatus 2 (paddle method) has become the workhorse instrument in the modem dissolution laboratory. It is expected to provide rugged and reproducible results, on which decisions about product quality, bioavaiI3bi~ty, bioequivalence etc. are based.
However, in practice, the apparatus tends to be extremely sensitive to outside and inside variables, ,vith large changes in dissolution profiles resulting from small changes in factors such as paddle rotational speed, vibration, deaeration and insertion of sampling probes (1,2). This can render results meaningless or impossible to interpret and thus constmle enonnous amounts of precious analyst rime in investigating, correcting and reva~dating the systems. It is largely for this reason that dissolution testing is usually regarded as nothing more than a mandated "service tool" of questionable perfonnance used only to satis/)' regulatory requirements, rather than a powerful predictive tool for pharmaceutical research and development (3).
Hydrodynamic Problems
Recent dissolution studies by Wang and Coffin (4) (Figure 1) . Much of the variability in dissolution rates observed using Apparatus 2 is attributable to this cone, since outcome. Also, the invisible liquid cone around non-disintegrating tablets is affected similarly. The rate controlling step of drug release from the product to the bulk dissolution medium often becomes the rate of release from the cone rather than the rate of release under 
Stirring Speed and Deaeration
C hanges in sti rring speed and the air bubbles whic h tend to form in nondeaerated media change th e flow characteristics of the media in conventiona l cylindrica l vessels and accelerate dispersion of th e cone, leading to erratic increases in dissolution rates compared to thorough ly deaerated media (I) . Because the cone is already effective ly we ll d ispersed in PEAK vesse ls, dissolution rates are not in fluenced by the presence of air bubbles, i.e., dissolution rates are the sa me, whether or not the medium is deaerated. 
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• Conventional vessels exhjbit marked differences in results between deaerated and nondeaerated media whereas PEAK vessels do not. Using both PEAK and conventiona l vessels at speeds of 50,75 and 100 rpm, the dissolution rates obtained in the former are at least twice that of the latter, are more reproducible, and differ little with changes in paddle rotational speed (Figures 6 & 7) . In contrast, dissolution rates in conventional vessels were extremely sensitive to padd le . ...
. . • has clea rl y demo nstrated that the larger the sample probe, the larger the disturbance, and therefore, the hi g her the rate (2). T I,is has fo rced the ana lysts to minimize both the size of sa mple pro bes and their residence time in the vessels. \~ith the use of PEAK vessels, th ese concerns are eliminated. This wi ll allow mllch greater freedom in sa mpling probe design, application and locatio n of indwelling fiber optics, temperature, and pH probes in the vessels to facilitate recording info l111atio n from each vessel during dissolution testing.
Peak Vessels and USP Calibrators
The present USP 300 mg sa li cylic acid non-) disin tegrating tablets are sujtable for use in PEAK ~ vessels; the corrected hydrodynamics wi ll mean that the specifications currentl y lIsed wi ll need to be eva luated and adjusted upwards.
The present US P 50 m g pr e dni so n e disintegrating tab lets are unsuitabl e, as they are even for ca Ubratio n o f the conve ntional vessels. T he NCDA 10 mg prednisone tablet wi ll be suit- 
Conclusions
The PEAK vessel eliminates ti,e hydrodynamic problems associated with conventional dissolution vesse ls by eliminating th e unstirred region underneath the paddle. Disturbances to this regi o n in conventional vessels result in significant variability in dissolu tion resul ts; elimination of this region in PEAK vessels make dissolution rates insensitive to the usual external and internal sources of variation. The adoption of tlh e PEAK vessel will result in Disso/lltiollTechll%giesIMAY 1996 higher degrees of confidence in resul ts and millim.i za tion of the time and effort now expended in runnin g USP system suitability tests. Dissolu tion results will now represent more correctl y the rate Umiring step of drug release in to soluti o n under sink conditions. These will form a firm foundation for in vitro -in vivo correlation
and tlh e setting o f meaningfuJ drug release specificati o ns for products based upo n the use of the USP Apparatus 2.
